At the drugmaker’s annual shareholders meeting, 61 percent of investors voted against the proposal while 38 percent backed the split. About 2 percent abstained from voting.
Allergan has spent the first quarter of 2019 fending off criticism from Appaloosa, an activist hedge fund that believes separating the roles is the necessary first step “toward arresting the steady decline of what was once a great company,” according to the report.
While Allergan agreed earlier this year to split the CEO and chairman roles at the next leadership transition, the hedge fund was dissatisfied with the plan, calling it a “half measure.”
Shortly afterward, a proposal was drafted to immediately split the roles, but the plan was struck down.
More articles on pharmacy:
10 hospitals seeking pharmacy leaders
Walgreens shaking up C-suite
Generic drugmakers could thrive in a recession, Moody’s says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
